Other · developed by Immunocore
IMC-C103C is an agent studied in select advanced solid tumors, given as a weekly subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03973333 | Phase 1/2 | Select Advanced Solid Tumors | Withdrawn | IMCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Select Advanced Solid Tumors
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMCR page.
See IMCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMCR catalysts and pipeline →